HIA
MDGL icon

Harbor Investment Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Harbor Investment Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
208
+194
+1,386% +$99.4K 0.01% 529
2026
Q1 		$7.33K Hold
14
– – ﹤0.01% 955
2025
Q4 		$8.15K Buy
+14
New +$7.15K ﹤0.01% 974

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Harbor Investment Advisory's MDGL Position: Q2 2026 in Review

Harbor Investment Advisory increased its Madrigal Pharmaceuticals (MDGL) stake by 1,386% in Q2 2026, buying an estimated $99.4K and bringing the position to 208 shares worth $112K. The position accounts for 0.01% of the portfolio, ranked #529.

Harbor Investment Advisory first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Harbor Investment Advisory held 208 shares of Madrigal Pharmaceuticals worth $112K as of Q2 2026.
  • Harbor Investment Advisory bought 194 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $99.4K.
  • Madrigal Pharmaceuticals made up 0.01% of Harbor Investment Advisory's portfolio in Q2 2026, its #529 holding.
  • Harbor Investment Advisory first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Harbor Investment Advisory's 13F filing for Q2 2026, filed 7 Jul 2026.